Several common metabolites and drugs in the serum of patients with inflammatory, infectious, autoimmune, immunodeficient, neoplastic, and toxicant-induced diseases can produce artifactual suppression of the [methyl-3H] A sensitive and specific in vitro assay is needed to detect and quantify serum factors and other soluble products that suppress mitogen-induced lymphocyte activation. Because of its semiautomation and compatibility with small blood sample sizes, the [methyl-3H]thymidine microtiter assay (1) has found rapid, widespread acceptance in the clinical laboratory. This assay usually affords an accurate assessment of lymphocyte responsiveness under conditions in which soluble test substances are not added to the cultures. However, with the addition of patients' sera or other complex mixtures of test substances, the assay becomes susceptible to errors because it inappropriately detects common interfering substances (2-8). Multiple types of interference occur because the ultimate incorporation of [methyl-3H]thymidine into lymphocyte DNA depends on four sequential processes: thymidine transport across the lymphocyte membrane, comixture of transported thymidine with various quantities of intracellularly synthesized thymidine, phosphorylation of thymidine to form the thymidine triphosphate precursor of DNA, and the true rate of DNA synthesis.
seimautomated, fluorescence-enhancement assay in which true Immunosuppressors are measured in the presence or absence of such interfering substances. Peripheral blood lymphocytes are activated with mitogens in standard microtiter culture trays. Changes in lymphocyte DNA content are quantified with a reagent formulation containing mithramycin, the fluorescence of which is enhanced on binding to DNA in the presence of MgCI2. We solubilize cells within the intact microtiter tray by using an automated, inverted "Array Sonicator," and measure fluorescence with an automated, photon-counting fluorometer. With this system, immune response modulation can be accurately assessed in the presence of patients' sara and other complex test substances (e.g., supernates from hybridomas, fermentation vats, viral preparations, and macrophage cultures).
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A sensitive and specific in vitro assay is needed to detect and quantify serum factors and other soluble products that suppress mitogen-induced lymphocyte activation. Because of its semiautomation and compatibility with small blood sample sizes, the [methyl-3H]thymidine microtiter assay (1) has found rapid, widespread acceptance in the clinical laboratory. This assay usually affords an accurate assessment of lymphocyte responsiveness under conditions in which soluble test substances are not added to the cultures. However, with the addition of patients' sera or other complex mixtures of test substances, the assay becomes susceptible to errors because it inappropriately detects common interfering substances (2) (3) (4) (5) (6) (7) (8) . Multiple types of interference occur because the ultimate incorporation of [methyl-3H]thymidine into lymphocyte DNA depends on four sequential processes: thymidine transport across the lymphocyte membrane, comixture of transported thymidine with various quantities of intracellularly synthesized thymidine, phosphorylation of thymidine to form the thymidine triphosphate precursor of DNA, and the true rate of DNA synthesis.
One or more of the first three processes can be altered by unlabeled thymidine and other nucleosides (2) (3) (4) (5) , ribaVirin (6) , coichicine (7) , and potentially many other natural and synthetic substances present in patients' sera and also in supernates from hybridoma, fermentation, viral, macrophage, and cell-line preparations (4, 5, 8) .
Hence, the [methyl -3Hjthymidine
assay cannot unambiguously assess immunotoxicant effects on lymphocyte activation. Direct determination of changes in lymphocyte DNA content circumvents these problems. In a preliminary study, we reported the development of a manual, microfluorometric assay for just such direct evaluations of immunotoxicants (9) . In- 
Materials and Methods

Specimens
Human blood is collected in polyethylene syringes, mixed with sodium heparin (100 kilo-usP units/L), and diluted with an equal volume of sterile saline. The lymphocytes and other mononuclear cells are enriched by Ficoll-Hypaque densitygradient centrifugation, as previously reported (10) . The resulting cells are cultured in quadruplicate samples in 96-well, round-bottom, microtiter trays (Limbro Scientific, Hainden, CT 06517) at 120 000 cells per well, for one to five days at 37 #{176}C in C02-enriched atmosphere (50 mLIL); each sample receives 200 L of RPMI 1640 medium containing human AB serum (80 mLIL, previously heated to 56#{176}C). For comparative studies, we used 96-well, flat-bottom culture trays (Falcon Model 3040 Microtest II; Becton, Dickinson and Co., Cockeysville, MD 21030). T lymphocytes are activated by the addition, at time zero, of a T-cell mitogen, either phytohemagglutinmn (PHA, type P; Difco Laboratories, Detroit, MI
48232),
2-40 mL/L, or Con A, 0.5-20.0 mg/L, prepared as previously described (11) .2 Alternatively, B lymphocytes are preferentially activated by the addition of pokeweed mitogen (Grand Island Biological Co., Grand Island, NY 14072), 1-50 mL/L, which works indirectly through the antecedent stimulation of T lymphocytes. Soluble test substances are added at time zero and left in place for the duration of culture (routinely, three days).
25004, Micromedic
Systems Inc., Rohm and Haas, Philadelphia, PA 19105). The disrupting solution consists of glassfiltered, aqueous, sodium dodecyl sulfate (SDS), 0.1 g/L; membrane-penetrating agent, dimethyl sulfoxide, 100 mL/L; and Tris base, 5 minol/L, all adjusted to a fmal pH of 7.4 with HC1. After letting the trays stand at 22 #{176}C for 30 mm, for partial disruption of cells and concomitant solubilization of DNA, we complete the disruption by sonicating the trays for an average of 20 s per well, using the inverted "Array Soulcator" described below. Sonication is required for acceptable assay precision.
We withdraw a 150-L aliquot of each microtiter sample from its well and, using the Micromedic pipetter, dilute with 1800 iL of fluorescence reagent and transfer simultaneously into a 12 X 75 mm polystyrene test tube. The fluorescence reagent consists of, per liter, 10 mmol of MgC12, 0. To measure the fluorescence of each aliquot, we load these tubes onto the automated sampler cassette of a Bio-Rad 
).
Baseline fluorescence (from unbound mithramycin) is included in both factors on the right-hand side of the equation, and hence is eliminated by subtraction of values for the unstimulated groups. Standard curves of fluorescence enhancement increments are generated at identical instrument settings for calf thymus type I DNA (Sigma Chemical Co., St. Louis, MO 63178) and for prefrozen, identically processed, resting peripheral blood lymphocytes.
Manual Sonication Methods
For studies comparing manual with automated sonication, the manual system involves the following changes of reagents and procedures: dimethyl sulfoxide is omitted from the lym- to its incorporation into the DNA fraction precipitated with TCA, 50 g/L (4). The mean counts per minute (cpm) and standard error of each quadruplicate sample are determined, and the stimulation index (SI) is calculated as follows:
To evaluate the specificity of the mithramycin microfluorometric assay for lymphocyte DNA vs RNA and other cellular constituents, we perform a parallel diphenylamine assay (13) to quantify the total deoxyribosyl residues of macromolecular DNA. Increments of unstimulated peripheral blood lymphocytes are pipetted into serial microtiter wells to produce a standard curve, and the wells are extracted twice with cold (4#{176}C) TCA (50 g/L). The samples are centrifuged as described (13) , and DNA content is evaluated by adding diphenylamine at 90-95 #{176}C for 10 mm in glacial acetic acid containing sulfuric acid (20 mL/L), then measuring the optical absorbance at 600 nm. Owing to the relative insensitivity of this assay, six replicate wells are required for each determination. 
Evaluation of Immunosuppressors
Special Apparatus
A prototype device, the "Array Sonicator," has been newly designed by one of us (D.F.R.) to automatically sonicate microtiter trays and arrays of test tubes, vials, and other small sample containers. This provides automated processing of cells for mithramycin labeling of DNA at a rate comparable to the processing of [methyl-3H]thymidine-labeled cells by multiple automated cell harvesters.
The major components of the Array Sonicator are shown in Figure 1 . We use a Heat Systems Model 431B, 2.5-in.-diameter inverted cuphorn to introduce sonic energy through the bath fluid of the Array Sonicator into the partially immersed samples. We modified the Lucite water-jacket that normally surrounds the cuphorn by cutting off the jacket at the level of the horn face and attaching a contiguous extension bath [24 (w) X 19(d) X 2.5 cm (h)]. To this, we added a sample carrier, an x-y actuator, and an electromechanical controller. During sonication, liquid coolant (equal volumes of ethylene glycol and water at 10 CC, to afford optimal energy transfer) is continuously recirculated through the sonicator bath by a thermostatically regulated proportioning pump (Model Lauda K-4/RD; Brinkmann Instruments, Inc., Westbury, NY 11590). The design of the bath is also compatible with simpler, nonproportioning pumps. The disruptor horn is driven by a Heat Systems Model W-370 Sonicator Cell Disruptor. For best sonication of round-and flat-bottom microtiter trays, we cover the trays with pre-cut, adhesive plate sealers (Dynetech Laboratories, Inc., Alexandria, VA 22314), and drill four airescape holes through the top plates of the trays (one at the center of each lateral skirt). The trays are positioned such that the well bottoms travel 1.2 cm above the top face of the disruptor horn. The sonicator power and sample dwell time are selected from settings of 30-80% of the maximum meter reading and 20-30s residence time per well, respectively, to optimize cell disruption in the desired brand and geometry of tray.
Results
A linear regression analysis of the mithramycin assay for double helical DNA vs a standard diphenylamine assay for deoxyribosyl residues of DNA (13) is shown in Figure 2 . Over the working range of 0-5 X 10 lymphocyte DNA equivalents commonly achieved in microtiter assays, the correlation coefficient is r = 0.91. The scatter of points is due predominantly to variation in diphenylarnine determinations, which results from sampling errors introduced by pooling the contents of six microtiter wells per determination, and to in- These substances produced no significant alterations of fluorescence intensities; hence, in all of the following experiments, the data reported were obtained by automated (array) For nonclinical applications, 6 7 longer culture gives increased sensitivity. Figure 5 compares the dose-response characteristics of the mithramycin and [methyl-3H]thymidine assays for lymphocytes stimulated with PHA. The response patterns and dose optima are similar, except that the dose range producing a maximal response is slightly narrower for the mithramycin assay. We further studied the relation between mithramycin and [methyl-3H]thymidine assays to determine whether responses are proportional to optimal doses of the three most widely used human lymphocyte mitogens: PHA, Con A, and pokeweed mitogen. The results are shown in Table 1 for the two T-cell mitogens, PHA and Con A. The ratio for the indirect-acting B-cell mitogen, pokeweed mitogen, is slightly higher. The basis for this difference remains to be elucidated.
In both assays, the responses are greater for T-cell mitogens than for the B-cell mitogen; however, the B-cell response is sufficient to allow detection and quantification of toxicants after the usual three days of culture. However, the ADA inhibitor, EHNA (16) , is suppressive at a lower concentration in the mithramycin assay than in the [methyl-3H]thymidine assay, indicating that the latter is comparatively insensitive for quantifying the immunological defect associated with at least one intracellular enzyme deficiency. When EHNA and adenosine are added together, in concentrations that simulate both the borderline intracellular enzyme defect and the moderately increased concentrations of plasma adenosine that Table 2 . ID50 Concentrations of Agents Tested against PHA-Stimulated Peripheral Blood Lymphocytes characterize most patients with ADA deficiency, the mithramycin assay is still slightly more sensitive than the radiolabel assay in detecting the combined functional defect. Addition of unlabeled thymidine produces an apparent suppression of the [methyl-3H]thymidine assay at concentrations 30-fold lower than in the mithramycin assay. This is caused by artifactual inhibition of the radiolabel assay at low, subblocking concentrations of thymidine, which have no effect on increments in lymphocyte DNA content. The mithramycin assay is unaffected by these low concentrations of interferent but becomes suppressed only by much higher (millimolar) concentrations, which have been documented by reliable but nonautomated techniques to block DNA synthesis and mitosis (4, 6, 8, 13, 14) . For all of the test substances in Table 2 , immunosuppression is obtained at comparable doses when pokeweed mitogen is used as the stimulant (data not shown). Therefore, we conclude that the mithramycin assay is both more specific and more sensitive than the [methyl-3H]thymidine assay for detecting suppressors of in vitro activation of T and B lymphocytes.
Because not only patients' sera but also certain hybridoma, fermentation, macrophage, and cell-line preparations accumulate variable mixtures of unlabeled thymidine and other nucleosides at interfering but sub-blocking concentrations (2-4, 14) , we have performed and separately reported experiments (9) in which various concentrations of PGE2 were mixed with a constant, low concentration of unlabeled thymidine. Results of these experiments show that the mithrarnycin assay correctly identifies and accurately quantifies a true immunosuppressor (PGE2) in both the presence and the absence of a known interfering substance (thymidine). producing an optimal response on culture day 3. C Cell controls, including uncultured cells and uncultured cells mixed with respective mitogen before assay, all give baseline (unstimulated) DNA values. Within-run and day-to-day CVs for three replicate runs over a three-day interval range from 7.9 to 13.5% and from 9.5 to 15.3%, respectively. d Within-run and day-to-day CVs for three replicate runs over a three-day interval range from 9.1 to 16.3% and from 10.7 to 19.6%, respectIvely.
Discussion
For the past decade, the [methyl-3H]thymidine microtiter assay (1) has provided a useful, first- clinical, environmental, and commercial applications. The assay we describe has extremely high specificity for native, helical DNA in preference to RNA, polynucleotides, polypeptides, and other cellular components (9, 23, 24 suppressors. The present assay should be particularly useful for distinguishing between the immunotoxicant and interfering effects of increased plasma adenosine and deoxyadenosine released by necrotic cells of leukemic patients undergoing treatment with deoxycoformycin and ara-A (25); increased mixed plasma nucleosides in patients with large tumors undergoing acute necrosis secondary to radiotherapy or high-dose chemotherapy; increased plasma adenosine (3-20 &mol/L) in patients with ADA deficiency (whose lymphocytes are abnormally sensitive to these nucleosides) (16, 26) ; blocking doses of thymidine (14) and nucleoside analogs (27, 28) ; ribavirin (6); colchicine (7); yincristine; and potentially other plant alkaloids.
The mithramycin assay may have extensive applications in the pharmaceutical industry for large-scale screening, identification, and purification of biological response modifiers initially present in crude form within fermentation, hybridoma, and cell-line supernates. Such products include the multiple interferons and new monoclonal antibodies directed against immune-response antigens and active against tumor growth. The latter can be assessed by using the present mi-thramycin indicator step in conjunction with modified donigenic assays. The mithramycin assay also can elucidate macrophage-mediator-lymphocyte interactions by affording accurate kinetic quantification of in vitro prostaglandin (15, 29) , interleukin, and interferon release in the presence of simultaneously released nucleosides (2-4, 18, 19) . This assay reduces or eliminates the biological hazards, licensing requirements, and expenses of radioisotopic procedures.
Although the Array Sonicator was initially developed for cell disruption in DNA-content assays, it has potential uses in other procedures requiring automated or sterile sonication of multiple samples, such as the dispersement or disruption of bacteria, viruses, and synthetic particles; the release of chromosomes from cells for automated chromosomal analysis; and the controlled or timed mixing of two-phase chemical and serological reactions, including the mixing of fluorescent immunospheres with fixation-stabilized target cells (30) .
